ECSP044974A - Formulación de suspensión oral estabilizada - Google Patents
Formulación de suspensión oral estabilizadaInfo
- Publication number
- ECSP044974A ECSP044974A EC2004004974A ECSP044974A ECSP044974A EC SP044974 A ECSP044974 A EC SP044974A EC 2004004974 A EC2004004974 A EC 2004004974A EC SP044974 A ECSP044974 A EC SP044974A EC SP044974 A ECSP044974 A EC SP044974A
- Authority
- EC
- Ecuador
- Prior art keywords
- formulation
- oral suspension
- stabilized oral
- thixotropic
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen composiciones farmacéuticas para administrar en forma oral que comprenden una droga de baja solubilidad en agua suspendida en un vehículo líquido acuoso que comprende un agente humectante, un agente espesante tixotrópico, y un agente de suspensión inorgánico. Las composiciones son tixotrópicas, sustancialmente desfloculadas y físicamente son estables de manera sustancial.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31037201P | 2001-08-06 | 2001-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP044974A true ECSP044974A (es) | 2004-03-23 |
Family
ID=23202195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2004004974A ECSP044974A (es) | 2001-08-06 | 2004-02-06 | Formulación de suspensión oral estabilizada |
Country Status (34)
Country | Link |
---|---|
US (2) | US20030108575A1 (es) |
EP (1) | EP1414409B1 (es) |
JP (1) | JP2005500363A (es) |
KR (1) | KR20040025740A (es) |
CN (1) | CN1287768C (es) |
AP (1) | AP1817A (es) |
AT (1) | ATE353627T1 (es) |
BR (1) | BR0211736A (es) |
CA (1) | CA2454173A1 (es) |
CO (1) | CO5560559A2 (es) |
CY (1) | CY1106548T1 (es) |
DE (1) | DE60218175T2 (es) |
DK (1) | DK1414409T3 (es) |
EA (1) | EA007901B1 (es) |
EC (1) | ECSP044974A (es) |
ES (1) | ES2280560T3 (es) |
GE (1) | GEP20074027B (es) |
HK (1) | HK1069542A1 (es) |
HR (1) | HRP20040118A2 (es) |
IL (1) | IL159551A0 (es) |
IS (1) | IS7126A (es) |
MA (1) | MA27054A1 (es) |
MX (1) | MXPA04001109A (es) |
MY (1) | MY135119A (es) |
NZ (1) | NZ530844A (es) |
OA (1) | OA12646A (es) |
PL (1) | PL366382A1 (es) |
PT (1) | PT1414409E (es) |
SI (1) | SI1414409T1 (es) |
TN (1) | TNSN04023A1 (es) |
UA (1) | UA80682C2 (es) |
WO (1) | WO2003013473A1 (es) |
YU (1) | YU7404A (es) |
ZA (1) | ZA200400639B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US20050036956A1 (en) * | 2003-08-15 | 2005-02-17 | Lin Fei | Non-aqueous liquid tooth whitening composition |
TR200301552A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Rofekoksib' in yeni oral farmakolojik formülasyonları. |
US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
US8318210B2 (en) * | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
US8653145B2 (en) * | 2005-09-22 | 2014-02-18 | Eaton Scientific Systems, Ltd. | Method for alleviating climacteric symptoms |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
DK2018153T3 (da) * | 2006-04-26 | 2012-07-23 | Rosemont Pharmaceuticals Ltd | Flydende orale sammensætninger |
CN100434072C (zh) * | 2006-06-19 | 2008-11-19 | 西安交通大学 | 具有抗炎性作用及改善血液流变性和抑制血栓形成的药物 |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
EP2280697A1 (en) | 2008-04-30 | 2011-02-09 | Wockhardt Research Centre | Oral liquid compositions of rhein or diacerein |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
WO2011107855A2 (en) | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
NZ602120A (en) | 2010-03-12 | 2015-02-27 | Monsanto Technology Llc | Agrochemical gel compositions |
AU2011260615B2 (en) * | 2010-06-02 | 2016-11-17 | Pharma& Schweiz Gmbh | Oral dosage forms of bendamustine |
EP2462922A1 (en) * | 2010-12-10 | 2012-06-13 | Bioprojet | New form of administration of enkephalinase inhibitor |
JPWO2012099142A1 (ja) * | 2011-01-18 | 2014-06-30 | 千寿製薬株式会社 | 保存効力を有するブロムフェナク水性液剤組成物 |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
BR112017025527A2 (pt) * | 2015-05-29 | 2018-08-07 | Kiel Laboratories Inc | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. |
EP3324856A4 (en) * | 2015-07-20 | 2019-03-27 | The Brigham and Women's Hospital, Inc. | SCHERVERDUNNENDE COMPOSITIONS AS INTRAVASCULAR EMBOLIC AGENT |
CN105902409B (zh) * | 2016-05-13 | 2019-03-05 | 广东龙湖科技股份有限公司 | 一种温和且具有触变性的牙膏 |
AU2017345473A1 (en) * | 2016-10-19 | 2019-04-18 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
WO2019070818A2 (en) * | 2017-10-04 | 2019-04-11 | Panacea Biomatx, Inc. | SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME |
CN112402376A (zh) * | 2019-08-22 | 2021-02-26 | 上海上药信谊药厂有限公司 | 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法 |
CN117883379A (zh) * | 2021-02-12 | 2024-04-16 | 浙江贝灵生物医药有限公司 | 一种口服碱性溶媒组合物及其制备方法与应用 |
WO2022185338A1 (en) * | 2021-03-05 | 2022-09-09 | Alkem Laboratories Limited | Stable oral suspension of celecoxib and method of preparation thereof |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684666A (en) * | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
EP0477289A4 (en) * | 1989-06-13 | 1992-07-22 | Abbott Laboratories | Anhydrous oil-based liquid suspension for delivering a medicament |
US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
US5616458A (en) * | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5401765A (en) * | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
US5475018A (en) * | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
NZ536355A (en) * | 1993-11-30 | 2006-08-31 | Searle & Co | Method of treating inflammation using substituted pyrazolyl benzenesulfonamides |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
US5418254A (en) * | 1994-05-04 | 1995-05-23 | G. D. Searle & Co. | Substituted cyclopentadienyl compounds for the treatment of inflammation |
WO1995030652A1 (en) * | 1994-05-04 | 1995-11-16 | G.D. Searle & Co. | Substituted spirodienes for the treatment of inflammation |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
AU3201095A (en) * | 1994-07-27 | 1996-02-22 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5420343A (en) * | 1994-08-31 | 1995-05-30 | G. D. Searle & Co. | Derivatives of aromatic cyclic alkylethers |
US5585504A (en) * | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
US5696143A (en) * | 1994-09-20 | 1997-12-09 | Talley; John J. | Benz G! indazolyl derivatives for the treatment of inflammation |
US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
ATE185797T1 (de) * | 1994-10-27 | 1999-11-15 | Merck Frosst Canada Inc | Stilben-derivate verwendbar als cyclooxygenase-2 hemmer |
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
JP2636819B2 (ja) * | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
US5552422A (en) * | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
AU4479096A (en) * | 1995-01-31 | 1996-08-21 | Merck Frosst Canada Inc. | 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2 |
US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
JP3996638B2 (ja) * | 1995-05-25 | 2007-10-24 | ジー.ディー.サール アンド カンパニー | 3−ハロアルキル−1h−ピラゾールの製造方法 |
US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
GB9514518D0 (en) * | 1995-07-15 | 1995-09-13 | Sod Conseils Rech Applic | Guanidine salt inhibitors of NO synthase and cyclooxygenase |
JPH0977664A (ja) * | 1995-09-13 | 1997-03-25 | Yakult Honsha Co Ltd | シクロオキシゲナーゼ−2特異的阻害剤及び抗炎症剤 |
US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
US6020343A (en) * | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US6057319A (en) * | 1995-10-30 | 2000-05-02 | Merck Frosst Canada & Co. | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
CA2242327A1 (en) * | 1996-01-11 | 1997-07-17 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US5789413A (en) * | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
GB9607503D0 (en) * | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
US5807873A (en) * | 1996-04-04 | 1998-09-15 | Laboratories Upsa | Diarylmethylidenefuran derivatives and their uses in therapeutics |
EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
US5922742A (en) * | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
US5883267A (en) * | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
US5741798A (en) * | 1996-06-03 | 1998-04-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents |
US5677318A (en) * | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
US5776967A (en) * | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
FR2751964B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique |
FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
US6005000A (en) * | 1996-08-22 | 1999-12-21 | Oxis International, Inc. | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor |
FR2753449B1 (fr) * | 1996-09-13 | 1998-12-04 | Union Pharma Scient Appl | Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique |
US5972950A (en) * | 1996-10-08 | 1999-10-26 | Laboratories Upsa | 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics |
US5681842A (en) * | 1996-11-08 | 1997-10-28 | Abbott Laboratories | Prostaglandin synthase-2 inhibitors |
US5869524A (en) * | 1996-11-12 | 1999-02-09 | American Home Products Corporation | Indene inhibitors of COX-2 |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
DK0946507T3 (da) * | 1996-12-10 | 2004-01-26 | Searle & Co | Substituerede pyrrolylforbindelser til behandling af inflammation |
US5973191A (en) * | 1996-12-30 | 1999-10-26 | Vanderbilt University | Selective inhibitors of prostaglandin endoperoxide synthase-2 |
US5929076A (en) * | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
US6071954A (en) * | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
US6004960A (en) * | 1997-03-14 | 1999-12-21 | Merck Frosst Canada, Inc. | Pyridazinones as inhibitors of cyclooxygenase-2 |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US6046217A (en) * | 1997-09-12 | 2000-04-04 | Merck Frosst Canada & Co. | 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 |
US6040450A (en) * | 1997-09-25 | 2000-03-21 | Merck & Co., Inc. | Process for making diaryl pyridines useful as cox-2-inhibitors |
FR2769311B1 (fr) * | 1997-10-07 | 1999-12-24 | Union Pharma Scient Appl | Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique |
US6133292A (en) * | 1997-10-30 | 2000-10-17 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors |
US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
FR2771412B1 (fr) * | 1997-11-26 | 2000-04-28 | Adir | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RS49945B (sr) * | 1998-04-24 | 2008-09-29 | Merck & Co.Inc., | Postupak za sintetizovanje inhibitora cox-2 |
US6077869A (en) * | 1998-10-29 | 2000-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6077868A (en) * | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
US6083969A (en) * | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
AU2298301A (en) * | 1999-10-20 | 2001-05-08 | Board Of Trustees Of Southern Illinois University, The | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
SK12672001A3 (sk) * | 1999-12-08 | 2002-04-04 | Pharmacia Corporation | Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku |
EP1274425A1 (en) * | 2000-04-18 | 2003-01-15 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
WO2002005799A2 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
GB0617119D0 (en) * | 2006-08-31 | 2006-10-11 | Renovo Ltd | Method of prognosis |
-
2002
- 2002-05-08 UA UA2004020879A patent/UA80682C2/uk unknown
- 2002-08-05 EA EA200400148A patent/EA007901B1/ru not_active IP Right Cessation
- 2002-08-05 EP EP02756952A patent/EP1414409B1/en not_active Expired - Lifetime
- 2002-08-05 ES ES02756952T patent/ES2280560T3/es not_active Expired - Lifetime
- 2002-08-05 WO PCT/US2002/024746 patent/WO2003013473A1/en active IP Right Grant
- 2002-08-05 BR BR0211736-3A patent/BR0211736A/pt not_active IP Right Cessation
- 2002-08-05 NZ NZ530844A patent/NZ530844A/en unknown
- 2002-08-05 DE DE60218175T patent/DE60218175T2/de not_active Expired - Fee Related
- 2002-08-05 SI SI200230516T patent/SI1414409T1/sl unknown
- 2002-08-05 OA OA1200400030A patent/OA12646A/en unknown
- 2002-08-05 PT PT02756952T patent/PT1414409E/pt unknown
- 2002-08-05 YU YU7404A patent/YU7404A/sh unknown
- 2002-08-05 IL IL15955102A patent/IL159551A0/xx unknown
- 2002-08-05 KR KR10-2004-7001860A patent/KR20040025740A/ko not_active Application Discontinuation
- 2002-08-05 GE GE5420A patent/GEP20074027B/en unknown
- 2002-08-05 AP APAP/P/2004/002969A patent/AP1817A/en active
- 2002-08-05 PL PL02366382A patent/PL366382A1/xx not_active Application Discontinuation
- 2002-08-05 CA CA002454173A patent/CA2454173A1/en not_active Abandoned
- 2002-08-05 US US10/212,308 patent/US20030108575A1/en not_active Abandoned
- 2002-08-05 MX MXPA04001109A patent/MXPA04001109A/es active IP Right Grant
- 2002-08-05 JP JP2003518483A patent/JP2005500363A/ja active Pending
- 2002-08-05 CN CNB02815522XA patent/CN1287768C/zh not_active Expired - Fee Related
- 2002-08-05 DK DK02756952T patent/DK1414409T3/da active
- 2002-08-05 AT AT02756952T patent/ATE353627T1/de not_active IP Right Cessation
- 2002-08-06 MY MYPI20022925A patent/MY135119A/en unknown
-
2004
- 2004-01-26 IS IS7126A patent/IS7126A/is unknown
- 2004-01-27 ZA ZA200400639A patent/ZA200400639B/en unknown
- 2004-01-27 MA MA27503A patent/MA27054A1/fr unknown
- 2004-02-03 HR HR20040118A patent/HRP20040118A2/hr not_active Application Discontinuation
- 2004-02-05 TN TNP2004000023A patent/TNSN04023A1/fr unknown
- 2004-02-06 EC EC2004004974A patent/ECSP044974A/es unknown
- 2004-02-06 CO CO04009302A patent/CO5560559A2/es not_active Application Discontinuation
-
2005
- 2005-03-14 HK HK05102202A patent/HK1069542A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 CY CY20071100568T patent/CY1106548T1/el unknown
- 2007-12-21 US US11/962,903 patent/US20090081309A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP044974A (es) | Formulación de suspensión oral estabilizada | |
PA8509001A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
HRP20060240T3 (en) | Intranasal formulation of rotigotine | |
NO20034149D0 (no) | Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel | |
ATE450250T1 (de) | Stabile zusammensetzung enhaltend partikel in einer gefrorenen wässrigen matrix | |
ES2190075T3 (es) | Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
AR038947A1 (es) | Suspension oral de sabor agradable y metodo | |
HRP20010878B1 (en) | Ziprasidone suspension | |
AR027554A1 (es) | Nuevo sistema de adminstracion de farmacos autoemulsionante | |
DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
CO5590911A2 (es) | Composiciones farmaceuticas a base de derivados de azetidina | |
PT1189595E (pt) | Composicoes oftalmicas sob a forma de geles aquosos | |
CL2004000496A1 (es) | Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente | |
SE0001916D0 (sv) | Novel formulation | |
BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
CR7245A (es) | Formulacion de suspension oral estabilizada | |
BRPI0510694A (pt) | composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole | |
HRP20020332B1 (en) | Oral solution containing galanthamine and a sweetening agent | |
NO20004816L (no) | Ny farmasøytisk formulering | |
HRP20070081T5 (en) | Nasal pharmaceutical composition of piribedil | |
MA27850A1 (fr) | Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate | |
ES2189639B1 (es) | Composicion acuosa que contiene acido acetilsalicilico. | |
ITRM20000624A0 (it) | Uso di derivati dell'acidocinnamico come agenti insetticidi. |